ISTH Advanced Training Course on platelet bleeding disorders: How should they be investigated?St. Anne's College, Oxford, 6-9th September 2016.

about

ISTH Advanced Training Course on platelet bleeding disorders: How should they be investigated?St. Anne's College, Oxford, 6-9th September 2016.

Item

http://www.wikidata.org/entity/Q40453216

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

ISTH Advanced Training Course ...... Oxford, 6-9th September 2016.

@en

type

Item

label

ISTH Advanced Training Course ...... Oxford, 6-9th September 2016.

@en

prefLabel

ISTH Advanced Training Course ...... Oxford, 6-9th September 2016.

@en

P1476

ISTH Advanced Training Course ...... , Oxford, 6-9th September 2016

@en

P2093

Andrew Paterson

http://www.w3.org/2001/XMLSchema#string

Gillian C Lowe

http://www.w3.org/2001/XMLSchema#string

Martina E Daly

http://www.w3.org/2001/XMLSchema#string

Steve P Watson

http://www.w3.org/2001/XMLSchema#string

Tim D Warner

http://www.w3.org/2001/XMLSchema#string

P2860

Genotyping and phenotyping of platelet function disorders

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects

Paris-Trousseau thrombocytopenia is phenocopied by the autosomal recessive inheritance of a DNA-binding domain mutation in FLI1.

Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects.

A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.

Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction.

Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study.

P304

719-721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09537104.2016.1256726

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Neil V Morgan

Paul Harrison

J Rivera

P577

2016-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27841701

http://www.w3.org/2001/XMLSchema#string